118 related articles for article (PubMed ID: 25169509)
1. Diagnostic relevance of overexpressed serine threonine tyrosine kinase/novel oncogene with kinase domain (STYK1/ NOK) mRNA in colorectal cancer.
Orang AV; Safaralizadeh R; Hosseinpour Feizi MA; Somi MH
Asian Pac J Cancer Prev; 2014; 15(16):6685-9. PubMed ID: 25169509
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of serine threonine tyrosine kinase 1/novel oncogene with kinase domain mRNA in patients with acute leukemia.
Kondoh T; Kobayashi D; Tsuji N; Kuribayashi K; Watanabe N
Exp Hematol; 2009 Jul; 37(7):824-30. PubMed ID: 19409952
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic relevance of overexpressed mRNA of novel oncogene with kinase-domain (NOK) in lung cancers.
Amachika T; Kobayashi D; Moriai R; Tsuji N; Watanabe N
Lung Cancer; 2007 Jun; 56(3):337-40. PubMed ID: 17298854
[TBL] [Abstract][Full Text] [Related]
4. A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment.
Kimbro KS; Duschene K; Willard M; Moore JA; Freeman S
Mol Biol Rep; 2008 Mar; 35(1):23-7. PubMed ID: 17415682
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic features and prognostic implications of NOK/STYK1 protein expression in non-small cell lung cancer.
Chen P; Li WM; Lu Q; Wang J; Yan XL; Zhang ZP; Li XF
BMC Cancer; 2014 Jun; 14():402. PubMed ID: 24894011
[TBL] [Abstract][Full Text] [Related]
6. Serine threonine tyrosine kinase 1 is a potential prognostic marker in colorectal cancer.
Hu L; Chen HY; Cai J; Zhang Y; Qi CY; Gong H; Zhai YX; Fu H; Yang GZ; Gao CF
BMC Cancer; 2015 Apr; 15():246. PubMed ID: 25884558
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic relevance of overexpressed NOK mRNA in breast cancer.
Moriai R; Kobayashi D; Amachika T; Tsuji N; Watanabe N
Anticancer Res; 2006; 26(6C):4969-73. PubMed ID: 17214372
[TBL] [Abstract][Full Text] [Related]
8. Significance of serine threonine tyrosine kinase 1 as a drug resistance factor and therapeutic predictor in acute leukemia.
Nirasawa S; Kobayashi D; Kondoh T; Kuribayashi K; Tanaka M; Yanagihara N; Watanabe N
Int J Oncol; 2014 Nov; 45(5):1867-74. PubMed ID: 25190507
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of GLUT3 impairs STYK1/NOK-mediated metabolic reprogramming and proliferation in NIH-3T3 cells.
Shi W; Fu Y; Wang Y
Oncol Lett; 2021 Jul; 22(1):527. PubMed ID: 34055092
[TBL] [Abstract][Full Text] [Related]
10. STYK1/NOK correlates with ferroptosis in non-small cell lung carcinoma.
Lai Y; Zhang Z; Li J; Li W; Huang Z; Zhang C; Li X; Zhao J
Biochem Biophys Res Commun; 2019 Nov; 519(4):659-666. PubMed ID: 31542233
[TBL] [Abstract][Full Text] [Related]
11. STYK1 promotes Warburg effect through PI3K/AKT signaling and predicts a poor prognosis in nasopharyngeal carcinoma.
Zhao Y; Yang L; He J; Yang H
Tumour Biol; 2017 Jul; 39(7):1010428317711644. PubMed ID: 28720063
[TBL] [Abstract][Full Text] [Related]
12. NOK/STYK1 interacts with GSK-3β and mediates Ser9 phosphorylation through activated Akt.
Li J; Wu F; Sheng F; Li YJ; Jin D; Ding X; Zhang S
FEBS Lett; 2012 Nov; 586(21):3787-92. PubMed ID: 23010592
[TBL] [Abstract][Full Text] [Related]
13. STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
Wang Z; Qu L; Deng B; Sun X; Wu S; Liao J; Fan J; Peng Z
Sci Rep; 2016 Sep; 6():33205. PubMed ID: 27628214
[TBL] [Abstract][Full Text] [Related]
14. NOK mediated mitogenic signaling is altered by P203L and V395I mutations.
Hou SQ; Liu L
Front Biosci (Landmark Ed); 2015 Jun; 20(7):1179-89. PubMed ID: 25961552
[TBL] [Abstract][Full Text] [Related]
15. Induction of chronic lymphocytic leukemia-like disease in STYK1/NOK transgenic mice.
Yang Y; Liu L; Tucker HO
Biochem Biophys Res Commun; 2022 Oct; 626():51-57. PubMed ID: 35970044
[TBL] [Abstract][Full Text] [Related]
16. A novel protein tyrosine kinase NOK that shares homology with platelet- derived growth factor/fibroblast growth factor receptors induces tumorigenesis and metastasis in nude mice.
Liu L; Yu XZ; Li TS; Song LX; Chen PL; Suo TL; Li YH; Wang SD; Chen Y; Ren YM; Zhang SP; Chang ZJ; Fu XY
Cancer Res; 2004 May; 64(10):3491-9. PubMed ID: 15150103
[TBL] [Abstract][Full Text] [Related]
17. STYK1/NOK affects cell cycle late mitosis and directly interacts with anaphase-promoting complex activator CDH1.
Zeng SL; Patel SS; Lv MQ; Zhu D; Shen WH; Liu L
Heliyon; 2022 Dec; 8(12):e12058. PubMed ID: 36506394
[TBL] [Abstract][Full Text] [Related]
18. NOK/STYK1 promotes the genesis and remodeling of blood and lymphatic vessels during tumor progression.
Liu Y; Li T; Hu D; Zhang S
Biochem Biophys Res Commun; 2016 Sep; 478(1):254-259. PubMed ID: 27444381
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of Serine Threonine Tyrosine Kinase 1 (STYK1) Inhibits the Migration and Tumorigenesis in Glioma Cells.
Zhou J; Wang F; Liu B; Yang L; Wang X; Liu Y
Oncol Res; 2017 Jul; 25(6):931-937. PubMed ID: 27983928
[TBL] [Abstract][Full Text] [Related]
20. NOK/STYK1 has a strong tendency towards forming aggregates and colocalises with epidermal growth factor receptor in endosomes.
Ding X; Jiang QB; Li R; Chen S; Zhang S
Biochem Biophys Res Commun; 2012 May; 421(3):468-73. PubMed ID: 22516751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
